CERo Therapeutics Holdings

CERO

Biotechnology · Healthcare

Price

$0.01

+0.00 (+11.11%)

Market Cap

$451,124

Exchange

Other OTC

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+57425.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7K (2021) → 4.2M (2025)

CERo Therapeutics is a small biotech company working on experimental cancer treatments. It is developing a type of cell therapy called "chimeric engulfment receptor" (CER-T) therapy, which trains a patient's own immune cells to find and destroy cancer cells. The company's potential customers are cancer patients and the hospitals and clinics that treat them.

CERo does not yet sell any products, so it earns no revenue — it is funded through investor capital while its treatments go through clinical trials. It operates primarily in the United States and, with a market cap near zero, is considered a micro-cap or nano-cap company. Its main competitive angle is its proprietary CER-T platform, which differs from more common CAR-T therapies by using macrophage-based immune cells instead of T-cells. The biggest risk the company faces is that its therapies may fail in clinical trials, and it will need to raise additional cash to continue operating.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+93.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$10M/ year

↑ Rising (+64% vs prior year)

R&D investment increasing — building for the future

Insider Activity

2.1%ownership

Relatively low insider ownership

Cash Runway

~1 months

$857,489 cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

CERo Therapeutics Holdings has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial